Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
12 participants
Study Classification
OBSERVATIONAL
Study Start Date
2014-06-30
Study Completion Date
2017-09-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is designed to develop pilot data on the acceptability and benefit of donor human milk for infants undergoing pharmacologic treatment for NAS. Specifically, gastrointestinal (GI) sub-scores, as well as total scores, will be compared between infants historically fed formula and those enrolled in a 2-week donor human milk study period.
Purpose of study: to test the following null hypothesis:
Infants with a diagnosis of neonatal abstinence syndrome (NAS) due to in-utero exposure to opiates, fed donor human milk, will have similar GI/feeding sub-scores of the Finnegan scoring tool when compared to (historic) infants fed formula.
A rejection of the null hypothesis will be used to design a randomized trial of donor human milk in infants with NAS.
Purpose of study: to test the following null hypothesis:
Infants with a diagnosis of neonatal abstinence syndrome (NAS) due to in-utero exposure to opiates, fed donor human milk, will have similar GI/feeding sub-scores of the Finnegan scoring tool when compared to (historic) infants fed formula.
A rejection of the null hypothesis will be used to design a randomized trial of donor human milk in infants with NAS.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Donor Milk vs. Formula in Extremely Low Birth Weight (ELBW) Infants
NCT01534481
Infant, Newborn
Infant, Small for Gestational Age
Infant, Extremely Low Birth Weight
COMPLETED
PHASE3
Human Milk for Congenital Gastrointestinal Disorders
NCT02567292
Congenital Gastrointestinal Disorders
COMPLETED
NA
Growth and Microbiome Development in Very Low Birth Weight Infants Fed Primarily Mother's Own Milk vs. Donor Human Milk
NCT02573779
Infant, Very Low Birth Weight
COMPLETED
Preterm Donor Human Milk Supplementation of Mother's Own Milk in VLBW Infants
NCT05675397
Prematurity
RECRUITING
NA
Phase II Growth and Safety Study of an Infant Formula for Healthy Term Infants
NCT04593147
Infant Development
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background
Neonatal Abstinence Syndrome (NAS) is a drug withdrawal syndrome that occurs primarily after antenatal exposure to opiates. Symptoms may be present at birth, but often peak at 48-72 after delivery. The onset of symptoms is affected by the half-life of the opiate used during pregnancy in combination with maternal and infant metabolism. The incidence of NAS has increased substantially since 2000 both nationally and in the Commonwealth of Kentucky, leading to a significant increase in healthcare resource utilization and (Figure 1).
The 2012 National Survey on Drug Use and Health found that illicit drug abuse affected \~130,000 pregnancies in the United States from 2011-2012 and that approximately 20% of those pregnancies (26,000) involved opiates. (SAMSA Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2009-2012). Patrick et al. utilized the Kids' Inpatient Database (KID) from the Agency for Health Care Research and Quality to evaluate the incidence of maternal opiate use during pregnancy (1). He and his team noted a substantial increase in the number of mothers using opiates - 1.19 per 1000 hospital births in 2000 to 5.63 per 1000 hospital births in 2009. As a result, there was an increased diagnosis of NAS from 1.20 per 1000 hospital births in 2000 to 3.39 per 1000 hospital births in 2009. This is a 2.8-fold increase which means that every hour of every day, 1 neonate in the United States undergoes drug withdrawal.
The Kentucky Injury Prevention and Research Center reported that 824 infants in the state of Kentucky were hospitalized for neonatal withdrawal after exposure to opiates in 2012. This represents an 18% increase from 2011 and a 4.5 fold increase from 2005. (Kentucky Injury Prevention and Research Center. Data for 2010-2012). NAS is an issue of epidemic proportions both for Kentucky and the nation. It results in prolonged hospitalizations and increased healthcare costs. In 2009, the total charges for NAS treatment were noted to be approximately $720 million nationally, up from approximately $190 million in 2000 (1). Kentucky data from 2012 report a $40 million dollar cost for neonatal drug withdrawal treatment, which has increased from $200,000 in 2000. (Kentucky Injury Prevention and Research Center. Data for 2010-2012). The majority of these costs (75-80%) are paid by the state Medicaid program (Figure 2).
Precipitous removal of exogenous opiates at the time of delivery results in unopposed stimulation by cyclic adenosine monophosphate (cAMP) and which increases norepinephrine levels and results in clinical symptoms of drug withdrawal in the neonate (2). Symptoms include central nervous system (CNS) signs (seizures, irritability, tremors), autonomic disturbances (sweating, yawning, nasal stuffiness, low grade fever, mottling) and gastrointestinal (GI) dysfunction (diarrhea, vomiting, poor feeding, and regurgitation). The cohort of withdrawal symptoms is dictated by the location of µ opioid receptors, which are concentrated in the brain but are also found in sensory nerves, mast cells and in the GI tract(3).
Treatment of withdrawal symptoms includes symptomatic care for mild symptoms and pharmacological intervention in addition to symptomatic care for moderate to severe symptoms. The American Academic of Pediatrics (AAP) and experts in the field recommend opioid replacement therapy as the first line pharmacologic intervention in opioid-induced withdrawal. The most commonly used medication is oral morphine. Phenobarbital and clonidine have been used as adjuvant therapies with some success in infants with more severe symptoms. Initiation, escalation and weaning of pharmacologic therapy are based on observer rated scales, the most common of which is the Finnegan Scale(4). Although observer-rated scales are an essential component in the assessment and treatment of neonatal drug withdrawal, they lack rigorous psychometric testing to establish reliability and validity, are subjective and have been difficult to standardize across nurseries (5).
Infants undergoing opiate withdrawal, as noted above, have feeding difficulty, including spitting, regurgitation and diarrhea. The Finnegan scoring tool includes a series of feeding assessments within the total scoring algorithm (Table 1). Human milk has been shown to be the best tolerated nutritional support for most infants and is cited by the AAP as the preferred method for feeding all infants (6). However, the AAP considers the use of marijuana, cocaine, methamphetamines and unsupervised opiate use during pregnancy to be a contraindication to breastfeeding (7). For most street drugs, the risks to the infant of ongoing active use by the mother outweigh the benefits of breastfeeding because the doses of the drug(s) being used and contaminants within the drug are unknown (8-11). The AAP does recognize that if a mother is in a supervised methadone treatment center and is free from using other drugs of abuse then breastfeeding is an essential component of the infant's care. However, most infants with NAS are fed formula for a variety of reasons, including concerns about continued maternal use.
Human milk is a complete nutritional food for the first 6 months of life in the term infant. Aside from its nutritional composition (specific for the support of the human infant), it contains hormones, immunoglobulins and growth factors that stimulate gastrointestinal growth and motility which, in turn, promote the maturation and protection of the GI tract. Mediators such as neurotensin and motilin promote GI motility while free amino acids feed intestinal growth (12,13). Human milk feeding has been shown to increase gastric emptying (14,15) and lactase activity (16) in the gut which improves feeding tolerance. A human milk diet is also associated with post-natal intestinal colonization by beneficial bacteria (Lactobacillus and Bifidobacteria). In summary, when compared to formula feeding, human milk appears to be a more suitable diet for the neonate at risk for GI dysfunction.
Two retrospective studies of the effect of breastfeeding on clinical symptoms of NAS have been reported. McQueen et al reviewed 28 mother-infant pairs with maternal methadone exposure and infant symptoms of NAS (17). Maternal and infant demographics were recorded along with feeding type, Finnegan scores and infant medication utilization during withdrawal. Feeding cohorts were created by quantifying the duration of breastfeeding during hospitalization. Formula fed infants received \>75% of all feedings as formula (n=9), breastfed infants received \>75% of feedings at the breast (n=8). The rest were considered combination feeders (n=11). Combination feeders were slightly less mature (35.6 weeks) and of lower birth weight (2608 g) than breastfed (38.8 weeks and 3025 g) or formula fed (39.1 weeks and 3302 grams). Breastfed infants received fewer scores, had significantly lower overall Finnegan scores and fewer scores \>8 when compared to formula and combination fed infants (p≤0.001).
Dryden et al. performed a retrospective cohort study of 437 infants born to women prescribed methadone in varying doses for their addiction (18). Median gestational age at birth was 38 weeks and birth weight was 2730 grams. Twenty-two percent of infants were breastfed for at least 72 hours. Multivariate logistic regression showed that the prescribed dose of methadone in these women independently influenced the likelihood of pharmacologic treatment for NAS (p\<0.001). However, for infants that were breastfed for at least 72 hours, the odds of needing pharmacologic treatment for NAS was significantly reduced (OR 0.55, 95% confidence interval 0.34 - 0.88, p=0.013).
Maternal opiates are transmitted through the breast milk to the infant. The amount of methadone and buprenorphine transferred in the breast milk has been found to be small, but may be significant enough to lead to some improvement in scores.
While these studies have reported improvements (decreases) in NAS scoring or reduced duration of treatment with breastfeeding, there are no reports that have looked at donor human milk, which is tested to be free of illicit drugs, and its effect on the GI sub-scores of the Finnegan algorithm. Given the general benefits of human milk for the human infant and these limited reports of improved neonatal well-being in breastfed infants with NAS, this study is designed to develop pilot data on the acceptability and benefit of donor human milk for infants undergoing pharmacologic treatment for NAS. Specifically, GI sub-scores, as well as total scores, will be compared between infants historically fed formula and those enrolled in a 2-week donor human milk study period.
Purpose of study: to test the following null hypothesis:
Infants with a diagnosis of neonatal abstinence syndrome (NAS) due to in-utero exposure to opiates, fed donor human milk, will have similar GI/feeding sub-scores of the Finnegan scoring tool when compared to (historic) infants fed formula.
A rejection of the null hypothesis will be used to design a randomized trial of donor human milk in infants with NAS.
Methods:
Once the infant's withdrawal symptoms have been stabilized with oral morphine and the mother has agreed to participation (signed informed consent and research authorization), infants will be assigned to receive only donor human milk (Co-op donor milk, Medolac Laboratories, Lake Oswego, OR) for a period of 2 weeks. Vitamin supplementation or other nutritional adjustments will be at the discretion of the attending physician.
Infant Finnegan scores will be assessed according to the current NAS protocol. Oral morphine dosing (increases or weaning doses) will be consistent with the current NAS protocol.
See data collection sheet for detailed list of variables.
Statistical analysis:
Descriptive statistics will be provided. As this is a pilot study, no inferential statistics will be applied.
Neonatal Abstinence Syndrome (NAS) is a drug withdrawal syndrome that occurs primarily after antenatal exposure to opiates. Symptoms may be present at birth, but often peak at 48-72 after delivery. The onset of symptoms is affected by the half-life of the opiate used during pregnancy in combination with maternal and infant metabolism. The incidence of NAS has increased substantially since 2000 both nationally and in the Commonwealth of Kentucky, leading to a significant increase in healthcare resource utilization and (Figure 1).
The 2012 National Survey on Drug Use and Health found that illicit drug abuse affected \~130,000 pregnancies in the United States from 2011-2012 and that approximately 20% of those pregnancies (26,000) involved opiates. (SAMSA Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2009-2012). Patrick et al. utilized the Kids' Inpatient Database (KID) from the Agency for Health Care Research and Quality to evaluate the incidence of maternal opiate use during pregnancy (1). He and his team noted a substantial increase in the number of mothers using opiates - 1.19 per 1000 hospital births in 2000 to 5.63 per 1000 hospital births in 2009. As a result, there was an increased diagnosis of NAS from 1.20 per 1000 hospital births in 2000 to 3.39 per 1000 hospital births in 2009. This is a 2.8-fold increase which means that every hour of every day, 1 neonate in the United States undergoes drug withdrawal.
The Kentucky Injury Prevention and Research Center reported that 824 infants in the state of Kentucky were hospitalized for neonatal withdrawal after exposure to opiates in 2012. This represents an 18% increase from 2011 and a 4.5 fold increase from 2005. (Kentucky Injury Prevention and Research Center. Data for 2010-2012). NAS is an issue of epidemic proportions both for Kentucky and the nation. It results in prolonged hospitalizations and increased healthcare costs. In 2009, the total charges for NAS treatment were noted to be approximately $720 million nationally, up from approximately $190 million in 2000 (1). Kentucky data from 2012 report a $40 million dollar cost for neonatal drug withdrawal treatment, which has increased from $200,000 in 2000. (Kentucky Injury Prevention and Research Center. Data for 2010-2012). The majority of these costs (75-80%) are paid by the state Medicaid program (Figure 2).
Precipitous removal of exogenous opiates at the time of delivery results in unopposed stimulation by cyclic adenosine monophosphate (cAMP) and which increases norepinephrine levels and results in clinical symptoms of drug withdrawal in the neonate (2). Symptoms include central nervous system (CNS) signs (seizures, irritability, tremors), autonomic disturbances (sweating, yawning, nasal stuffiness, low grade fever, mottling) and gastrointestinal (GI) dysfunction (diarrhea, vomiting, poor feeding, and regurgitation). The cohort of withdrawal symptoms is dictated by the location of µ opioid receptors, which are concentrated in the brain but are also found in sensory nerves, mast cells and in the GI tract(3).
Treatment of withdrawal symptoms includes symptomatic care for mild symptoms and pharmacological intervention in addition to symptomatic care for moderate to severe symptoms. The American Academic of Pediatrics (AAP) and experts in the field recommend opioid replacement therapy as the first line pharmacologic intervention in opioid-induced withdrawal. The most commonly used medication is oral morphine. Phenobarbital and clonidine have been used as adjuvant therapies with some success in infants with more severe symptoms. Initiation, escalation and weaning of pharmacologic therapy are based on observer rated scales, the most common of which is the Finnegan Scale(4). Although observer-rated scales are an essential component in the assessment and treatment of neonatal drug withdrawal, they lack rigorous psychometric testing to establish reliability and validity, are subjective and have been difficult to standardize across nurseries (5).
Infants undergoing opiate withdrawal, as noted above, have feeding difficulty, including spitting, regurgitation and diarrhea. The Finnegan scoring tool includes a series of feeding assessments within the total scoring algorithm (Table 1). Human milk has been shown to be the best tolerated nutritional support for most infants and is cited by the AAP as the preferred method for feeding all infants (6). However, the AAP considers the use of marijuana, cocaine, methamphetamines and unsupervised opiate use during pregnancy to be a contraindication to breastfeeding (7). For most street drugs, the risks to the infant of ongoing active use by the mother outweigh the benefits of breastfeeding because the doses of the drug(s) being used and contaminants within the drug are unknown (8-11). The AAP does recognize that if a mother is in a supervised methadone treatment center and is free from using other drugs of abuse then breastfeeding is an essential component of the infant's care. However, most infants with NAS are fed formula for a variety of reasons, including concerns about continued maternal use.
Human milk is a complete nutritional food for the first 6 months of life in the term infant. Aside from its nutritional composition (specific for the support of the human infant), it contains hormones, immunoglobulins and growth factors that stimulate gastrointestinal growth and motility which, in turn, promote the maturation and protection of the GI tract. Mediators such as neurotensin and motilin promote GI motility while free amino acids feed intestinal growth (12,13). Human milk feeding has been shown to increase gastric emptying (14,15) and lactase activity (16) in the gut which improves feeding tolerance. A human milk diet is also associated with post-natal intestinal colonization by beneficial bacteria (Lactobacillus and Bifidobacteria). In summary, when compared to formula feeding, human milk appears to be a more suitable diet for the neonate at risk for GI dysfunction.
Two retrospective studies of the effect of breastfeeding on clinical symptoms of NAS have been reported. McQueen et al reviewed 28 mother-infant pairs with maternal methadone exposure and infant symptoms of NAS (17). Maternal and infant demographics were recorded along with feeding type, Finnegan scores and infant medication utilization during withdrawal. Feeding cohorts were created by quantifying the duration of breastfeeding during hospitalization. Formula fed infants received \>75% of all feedings as formula (n=9), breastfed infants received \>75% of feedings at the breast (n=8). The rest were considered combination feeders (n=11). Combination feeders were slightly less mature (35.6 weeks) and of lower birth weight (2608 g) than breastfed (38.8 weeks and 3025 g) or formula fed (39.1 weeks and 3302 grams). Breastfed infants received fewer scores, had significantly lower overall Finnegan scores and fewer scores \>8 when compared to formula and combination fed infants (p≤0.001).
Dryden et al. performed a retrospective cohort study of 437 infants born to women prescribed methadone in varying doses for their addiction (18). Median gestational age at birth was 38 weeks and birth weight was 2730 grams. Twenty-two percent of infants were breastfed for at least 72 hours. Multivariate logistic regression showed that the prescribed dose of methadone in these women independently influenced the likelihood of pharmacologic treatment for NAS (p\<0.001). However, for infants that were breastfed for at least 72 hours, the odds of needing pharmacologic treatment for NAS was significantly reduced (OR 0.55, 95% confidence interval 0.34 - 0.88, p=0.013).
Maternal opiates are transmitted through the breast milk to the infant. The amount of methadone and buprenorphine transferred in the breast milk has been found to be small, but may be significant enough to lead to some improvement in scores.
While these studies have reported improvements (decreases) in NAS scoring or reduced duration of treatment with breastfeeding, there are no reports that have looked at donor human milk, which is tested to be free of illicit drugs, and its effect on the GI sub-scores of the Finnegan algorithm. Given the general benefits of human milk for the human infant and these limited reports of improved neonatal well-being in breastfed infants with NAS, this study is designed to develop pilot data on the acceptability and benefit of donor human milk for infants undergoing pharmacologic treatment for NAS. Specifically, GI sub-scores, as well as total scores, will be compared between infants historically fed formula and those enrolled in a 2-week donor human milk study period.
Purpose of study: to test the following null hypothesis:
Infants with a diagnosis of neonatal abstinence syndrome (NAS) due to in-utero exposure to opiates, fed donor human milk, will have similar GI/feeding sub-scores of the Finnegan scoring tool when compared to (historic) infants fed formula.
A rejection of the null hypothesis will be used to design a randomized trial of donor human milk in infants with NAS.
Methods:
Once the infant's withdrawal symptoms have been stabilized with oral morphine and the mother has agreed to participation (signed informed consent and research authorization), infants will be assigned to receive only donor human milk (Co-op donor milk, Medolac Laboratories, Lake Oswego, OR) for a period of 2 weeks. Vitamin supplementation or other nutritional adjustments will be at the discretion of the attending physician.
Infant Finnegan scores will be assessed according to the current NAS protocol. Oral morphine dosing (increases or weaning doses) will be consistent with the current NAS protocol.
See data collection sheet for detailed list of variables.
Statistical analysis:
Descriptive statistics will be provided. As this is a pilot study, no inferential statistics will be applied.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neonatal Abstinence Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DHM
Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk
donor human milk
Intervention Type
DIETARY_SUPPLEMENT
Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.
GI-subscores from the Finnegan NAS Scoring system will be computed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
donor human milk
Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.
GI-subscores from the Finnegan NAS Scoring system will be computed.
Intervention Type
DIETARY_SUPPLEMENT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Co-op donor milk (Medolac Laboratories)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Term infants (\>37 completed weeks) with a diagnosis of NAS, due to maternal use of opiates (only)
* Infants will have had moderate to severe NAS symptoms (Finnegan scores \>8) that required pharmacologic therapy but have been stabilized (captured) on oral morphine (Finnegan scores less than 8 for 24 hours)
* Breastfeeding is contraindicated or the mother has chosen formula feeding for her baby
* Infants will have had moderate to severe NAS symptoms (Finnegan scores \>8) that required pharmacologic therapy but have been stabilized (captured) on oral morphine (Finnegan scores less than 8 for 24 hours)
* Breastfeeding is contraindicated or the mother has chosen formula feeding for her baby
Exclusion Criteria
* Preterm infants (\<37 completed weeks at birth)
* Infants with intrauterine growth restriction (BW \<10th percentile for gestational age)
* Mother is providing her own milk
* Infants with intrauterine growth restriction (BW \<10th percentile for gestational age)
* Mother is providing her own milk
Minimum Eligible Age
38 Weeks
Maximum Eligible Age
42 Weeks
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Louisville
OTHER
Sponsor Role
collaborator
Neolac Inc dba Medolac Laboratories
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lori Devlin, DO, MHA
Role: PRINCIPAL_INVESTIGATOR
University of Louisville Division of Neonatal Medicine
Paula G Radmacher, MSPH, Ph.D.
Role: STUDY_DIRECTOR
University of Louisville Division of Neonatal Medicine
Scott Duncan, MD
Role: PRINCIPAL_INVESTIGATOR
University of Louisville Division of Neonatal Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Louisville
Louisville, Kentucky, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012 May 9;307(18):1934-40. doi: 10.1001/jama.2012.3951. Epub 2012 Apr 30.
Reference Type
BACKGROUND
Nestler EJ. Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol. 1997 Oct;7(5):713-9. doi: 10.1016/s0959-4388(97)80094-3.
Reference Type
BACKGROUND
Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005 Mar;57(1):1-26. doi: 10.1124/pr.57.1.1.
Reference Type
BACKGROUND
Kron RE, Finnegan LP, Kaplan SL, Litt M, Phoenix MD. The assessment of behavioral change in infants undergoing narcotic withdrawal: comparative data from clinical and objective methods. Addict Dis. 1975;2(1-2):257-75.
Reference Type
BACKGROUND
Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs. Pediatrics. 1998 Jun;101(6):1079-88.
Reference Type
BACKGROUND
Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2012 Mar;129(3):e827-41. doi: 10.1542/peds.2011-3552. Epub 2012 Feb 27.
Reference Type
BACKGROUND
Behnke M, Smith VC; Committee on Substance Abuse; Committee on Fetus and Newborn. Prenatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics. 2013 Mar;131(3):e1009-24. doi: 10.1542/peds.2012-3931. Epub 2013 Feb 25.
Reference Type
BACKGROUND
Chasnoff IJ, Lewis DE, Squires L. Cocaine intoxication in a breast-fed infant. Pediatrics. 1987 Dec;80(6):836-8.
Reference Type
BACKGROUND
COBRINIK RW, HOOD RT Jr, CHUSID E. The effect of maternal narcotic addiction on the newborn infant; review of literature and report of 22 cases. Pediatrics. 1959 Aug;24(2):288-304. No abstract available.
Reference Type
BACKGROUND
Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med. 1982 Sep 23;307(13):819-20. doi: 10.1056/NEJM198209233071311. No abstract available.
Reference Type
BACKGROUND
Steiner E, Villen T, Hallberg M, Rane A. Amphetamine secretion in breast milk. Eur J Clin Pharmacol. 1984;27(1):123-4.
Reference Type
BACKGROUND
Rodriguez-Palmero M, Koletzko B, Kunz C, Jensen R. Nutritional and biochemical properties of human milk: II. Lipids, micronutrients, and bioactive factors. Clin Perinatol. 1999 Jun;26(2):335-59.
Reference Type
BACKGROUND
Sheard NF, Walker WA. The role of breast milk in the development of the gastrointestinal tract. Nutr Rev. 1988 Jan;46(1):1-8. doi: 10.1111/j.1753-4887.1988.tb05343.x. No abstract available.
Reference Type
BACKGROUND
Billeaud C, Guillet J, Sandler B. Gastric emptying in infants with or without gastro-oesophageal reflux according to the type of milk. Eur J Clin Nutr. 1990 Aug;44(8):577-83.
Reference Type
BACKGROUND
Cavell B. Gastric emptying in infants fed human milk or infant formula. Acta Paediatr Scand. 1981 Sep;70(5):639-41.
Reference Type
BACKGROUND
Alexander C, Radmacher P, Devlin L. Donor human milk may decrease severe gastrointestinal distress in infants with neonatal abstinence syndrome. Pregnancy and neonatal medicine 2017; 1(1):11-15.
Reference Type
RESULT
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAS 052014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
NCT02953223
COMPLETED
Neokare Safety and Tolerability Assessment in Neonates With GI Problems
NCT05293353
UNKNOWN
Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair
NCT02575846
COMPLETED
NA
Acceptability and Tolerance Study of an Amino Acid Formula with HMOs
NCT04575298
TERMINATED
Transition From Donor Milk: a Feasibility Study
NCT06514014
RECRUITING
NA
Comparing Impacts of Donor Human Milk to Formula Supplementation on the Gut Microbiome of Full-term Infants
NCT05815433
ACTIVE_NOT_RECRUITING
NA
The Effect of Cow Milk Consumption on Respiratory Symptoms and Pulmonary Functions in Asthmatic and Non Asthmatic Children
NCT02745899
UNKNOWN
NA
Tolerance of Healthy Infants Fed Infant Formulas
NCT02401217
COMPLETED
NA
Healthy Term Infants Fed Milk-Based Infant Formula
NCT04529759
COMPLETED
NA
Impact of Preterm Single Donor Milk in Very Low Birth Weight Infants
NCT02216292
COMPLETED
Nutritive Effects of Cow's Milk-Based Formulas Through 18 Months of Age
NCT04859231
TERMINATED
NA
Oral Administration of Colostrum to Premature Babies: Impact on the Oral Microbiota
NCT02306980
COMPLETED
NA
The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies
NCT06072976
UNKNOWN
NA
Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy
NCT02379598
COMPLETED
The Role of Human Milk Oligosaccharides and Microbiomes on Infantile Colic and Atopic Dermatitis in Term Infants
NCT05992493
ACTIVE_NOT_RECRUITING
Promotion of Thickened Feeds to Manage Newborns With Feeding Difficulties
NCT00859092
COMPLETED
PHASE2
Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy
NCT04910373
TERMINATED
NA
Interdisciplinary Pharmaceutical Analysis: Artificial Milk Effects on Children and Postnatal Women's Health
NCT06653309
COMPLETED
Treatment of Gastroesophageal Reflux Disease in Infants
NCT06255886
RECRUITING
PHASE4
Growth and Nutritional Status of Very Low Birth Weight Infants Fed a High Protein Exclusive Human Milk Diet
NCT03839173
UNKNOWN
NA
Study of the Relationship Between Feeding and Late Onset Sepsis and/or Necrotizing Enterocolitis in Low Birth Weight Infants
NCT00005888
COMPLETED
NA
Effect of Ingestion of Human, Cow, and Modified-cow Milk, on Glucose and Hormone Responses in Humans.
NCT04698889
COMPLETED
NA
Effects of Infant Formula Composition on Infant Feeding Behaviors
NCT00957892
COMPLETED
Human Milk Oligosaccharides (HMOs) Post-market Study on Infants (NEHMO)
NCT05150288
COMPLETED
NA
Infant Formula in Infants and Children With Cow's Milk Allergy
NCT06456541
RECRUITING
NA